Monogram and Avexa Sign HIV Drug Research Agreement
Posted on: Tuesday, 11 March 2008, 06:00 CDT
Monogram Biosciences has signed an agreement with Avexa to be the exclusive provider of HIV resistance and tropism testing technology in support of Avexa's drug discovery and development programs.
Avexa plans to use Monogram's assays across its virology portfolio, including the Phase III program for its lead compound, apricitabine, an anti-HIV drug. Avexa also plans to use Monogram's PhenoSense GT assay to select patients and optimize background therapy for trials involving approximately 2,000 patients, and to monitor response to drug treatment during the trials.
Julian Chick, Avexa's CEO, said: "Monogram has an impressive portfolio of tests that we believe provide the accuracy and reliability that are necessary for studies that are intended to be submitted to the FDA and other regulatory agencies."
Source: Datamonitor
Related Articles
- Cytopia Letter to Progen Shareholders
- Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
- Avexa Initiates Phase III Trial of HIV Drug
- Avexa to Start Phase III Program for HIV Drug
- HIV Drug Well-Tolerated in Mid-Stage Trial, Says Avexa
- Avexa Wins $4.3m Commercial Ready Grant for Anti-HIV Drug Discovery Program
- Avexa HIV Drug Meets Trial Goal
- Monogram to Collaborate on Merck HIV Compound
- Monogram Biosciences Announces Medicaid Coverage for HIV Drug Resistance Testing in Texas
 |
 |
User Comments (0)
RSS Feeds